Reata Pharmaceuticals Sustainability Profile
Reata Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States, with significant operations across various regions. Founded in 2008, Reata focuses on developing innovative therapies for serious diseases, particularly in the fields of neurology and rare diseases. The company is renowned for its unique product offerings, including its lead drug, which targets critical pathways in cellular metabolism. Reata's commitment to advancing treatment options has positioned it as a leader in the market, achieving notable milestones in clinical development and regulatory approvals. With a strong emphasis on scientific innovation, Reata Pharmaceuticals continues to make strides in improving patient outcomes and addressing unmet medical needs.
DitchCarbon Score
How does Reata Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Reata Pharmaceuticals's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Reata Pharmaceuticals, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Biogen Inc., and as such, it inherits emissions data and climate commitments from its parent organisation. Reata Pharmaceuticals has not publicly disclosed any specific reduction targets or initiatives. However, it is important to note that its climate commitments and performance metrics are influenced by Biogen Inc.'s sustainability strategies. Biogen has established various initiatives, including participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), which aim to reduce greenhouse gas emissions across its operations. As a subsidiary, Reata Pharmaceuticals aligns with Biogen's broader climate goals, although specific targets or achievements for Reata itself have not been detailed. The company is expected to contribute to the overarching sustainability efforts of its parent organisation, focusing on reducing emissions and enhancing environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 55,965,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 390,000 | 000,000 | 000,000 | 00,000 | 00,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | 235,589,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Reata Pharmaceuticals's Industry?
How Carbon Intensive is Reata Pharmaceuticals's Location?
Reata Pharmaceuticals's Scope 3 Categories Breakdown
Reata Pharmaceuticals's Scope 3 emissions, which decreased by 12% last year and increased by approximately 13% since 2014, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 69% of Scope 3 emissions.
Top Scope 3 Categories
Reata Pharmaceuticals's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Reata Pharmaceuticals has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
